Logo image of ARMO

ARMO BIOSCIENCES INC (ARMO) Stock Price, Forecast & Analysis

USA - Nasdaq - NASDAQ:ARMO - US04225U1043

49.98
+0.01 (+0.02%)
Last: 6/21/2018, 8:13:59 PM
49.94
-0.04 (-0.08%)
After Hours: 6/21/2018, 8:13:59 PM

ARMO Key Statistics, Chart & Performance

Key Statistics
Market Cap1.52B
Revenue(TTM)N/A
Net Income(TTM)-42.42M
Shares30.41M
FloatN/A
52 Week High57.19
52 Week Low25.1
Yearly Dividend0
Dividend Yield0%
EPS(TTM)-28.52
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPON/A
Sector
GICS SectorN/A
GICS IndustryN/A
GICS IndustryGroupN/A
GICS SubIndustryN/A


ARMO short term performance overview.The bars show the price performance of ARMO in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 10 15 20 25

ARMO long term performance overview.The bars show the price performance of ARMO in the last 1, 2 and 3 years. 1 year 2 years 3 years

The current stock price of ARMO is 49.98 null. In the past month the price increased by 0.16%.

ARMO BIOSCIENCES INC / ARMO Daily stock chart

About ARMO

Company Profile

ARMO Biosciences, Inc. is a clinical-stage biopharmaceutical company. It focuses on developing immunotherapies for the treatment of cancer, cardiovascular disease, fibrosis and inflammation. The Company's platform molecule AM0010 is a pegylated form of recombinant human IL-10, which has immune stimulating effects which induce the activation, proliferation and survival of intratumoral, tumor-reactive, cytotoxic CD8 T cells in cancer patients. Its product pipeline includes AM0001, an anti-PD-1 checkpoint inhibitor; AM0003 an anti-LAG-3 checkpoint inhibitor; AM0015 a form of recombinant human Interleukin-15 cytokine and AM0012 a form of recombinant human Interleukin-12 cytokine. ARMO Biosciences, Inc. is based in REDWOOD CITY, United States.

Company Info

ARMO BIOSCIENCES INC

575 Chesapeake Drive

Redwood City CA 94063

CEO: Peter Van Vlasselaer

Phone: 650-779-5075

ARMO BIOSCIENCES INC / ARMO FAQ

What does ARMO do?

ARMO Biosciences, Inc. is a clinical-stage biopharmaceutical company. It focuses on developing immunotherapies for the treatment of cancer, cardiovascular disease, fibrosis and inflammation. The Company's platform molecule AM0010 is a pegylated form of recombinant human IL-10, which has immune stimulating effects which induce the activation, proliferation and survival of intratumoral, tumor-reactive, cytotoxic CD8 T cells in cancer patients. Its product pipeline includes AM0001, an anti-PD-1 checkpoint inhibitor; AM0003 an anti-LAG-3 checkpoint inhibitor; AM0015 a form of recombinant human Interleukin-15 cytokine and AM0012 a form of recombinant human Interleukin-12 cytokine. ARMO Biosciences, Inc. is based in REDWOOD CITY, United States.


What is the stock price of ARMO BIOSCIENCES INC today?

The current stock price of ARMO is 49.98 null. The price increased by 0.02% in the last trading session.


Does ARMO stock pay dividends?

ARMO does not pay a dividend.


How is the ChartMill rating for ARMO BIOSCIENCES INC?

ARMO has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


Which stock exchange lists ARMO stock?

ARMO stock is listed on the Nasdaq exchange.


What is ARMO BIOSCIENCES INC worth?

ARMO BIOSCIENCES INC (ARMO) has a market capitalization of 1.52B null. This makes ARMO a Small Cap stock.


ARMO Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to ARMO.


Chartmill TA Rating
Chartmill Setup Rating

ARMO Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to ARMO. ARMO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ARMO Financial Highlights

Over the last trailing twelve months ARMO reported a non-GAAP Earnings per Share(EPS) of -28.52. The EPS decreased by -8.7% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -24.23%
ROE -27.05%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%N/A
Sales Q2Q%N/A
EPS 1Y (TTM)-8.7%
Revenue 1Y (TTM)N/A

ARMO Forecast & Estimates


Analysts
AnalystsN/A
Price TargetN/A
EPS Next Y91.8%
Revenue Next YearN/A

ARMO Ownership

Ownership
Inst Owners40.94%
Ins OwnersN/A
Short Float %N/A
Short RatioN/A